| Literature DB >> 31217034 |
Mirjana Kocova1, Violeta Anastasovska2, Iskra Bitovska3.
Abstract
BACKGROUND: The simple virilizing (SV) form of congenital adrenal hyperplasia (CAH) is an autosomal recessive disorder usually caused by steroid 21-hydroxylase deficiency due to I172N missense mutation at the CYP21A2 gene. Clinical presentation encompasses virilization of external genitalia in newborn females and pseudoprecocious puberty in both sexes, due to reactive androgen overproduction. The aim of this study was to present two sisters with an SV form of CAH and distinctive genotype, detected and treated since childhood with a poor compliance and poor metabolic control hindering the fertility. CASEEntities:
Keywords: CYP21A2 gene; Congenital adrenal hyperplasia; Infertility; Simple virilizing form
Year: 2019 PMID: 31217034 PMCID: PMC6582564 DOI: 10.1186/s40001-019-0379-4
Source DB: PubMed Journal: Eur J Med Res ISSN: 0949-2321 Impact factor: 2.175
Baseline evaluation and management in infancy and childhood
| Patient 1 | Patient 2 | |
|---|---|---|
| Gender assignment at birth | Female | Female |
| Age at diagnosed of CAH | 7 years | 9 years |
| Degree of genital virilization at birth | Prader stage 1 clitoromegaly (1 cm) | Prader stage 2 clitoromegaly (1.5 cm) |
| Age at start of menarche | 16 years irregularly | 18 years irregularly |
| CAH genetics | Compound heterozygote | Compound heterozygote |
| CYP21A2 mutations | P30L/I172N | P30L/I172N |
| CAH classification at diagnosis | Simple virilizing | Simple virilizing |
| Steroid hormone results at the time of diagnosis of CAH—before treatment | ||
| 17-OHP (ref. 0.3–3) | > 75 nmol/L | > 75 nmol/L |
| Testosterone (ref. 0.3–3) | 29.8 nmol/L | 19.6 nmol/L |
| Urinary 17-ketosteroids (ref. 13.8–43.4) | 88.7 dU/µmol | 50.6 dU/µmol |
| Urinary 17-corticosteroids (ref. 11.7–36.6) | 46.8 dU/µmol | 36.6 dU/µmol |
| Steroid hormone results—with hydrocortisone 20 mg/m2 treatment | ||
| 17-OHP | 56.5 nmol/L | 29.5 nmol/L |
| Testosterone (ref. < 0.1–0.96) | 2.8 ng/mL | 3.2 ng/mL |
| Urinary 17-ketosteroids | 20 dU/µmol | 32.3 dU/µmol |
| Urinary 17-corticosteroids | 18.8 dU/µmol | 16.6 dU/µmol |
Fig. 1ACRS/PCR mutational analysis of the CYP21A2 gene; line 1—PCR II product; lines 2, 3—compound heterozygous patients with genotype P30L/I172N; lines 4, 5—others two sisters, heterozygotes for I172N; line 6—father, heterozygote for P30L; line 7—blank; M—marker (50 bp)
Fig. 2Male distribution of body hair in sisters with simple virilizing CAH
Follow-up evaluation in adulthood
| Patient 1 | Patient 2 | |
|---|---|---|
| Age at latest evaluation | 35 years | 38 years |
| General appearance in both sisters | Hirsutism on face with mustache, male distribution of body hair, athletic constitution of body, underdeveloped breast | |
| Current medications in both | Dexamethasone 0.5 mg/day + hydrocortisone 10 mg/day | |
| Surgical procedures | No surgical procedures | Clitoroplasty and vaginoplasty |
| In vitro fertilization | 2017—ongoing | 2012, 2014, 2016—unsuccessfully |
| Steroid hormone results at latest evaluation—with treatment | ||
| 17-OHP (ref. 0.2–2.9 ng/mL) | 29 ng/mL | 27 ng/mL |
| Testosterone (ref. < 2.1 nmol/L) | 0.087 nmol/L | 0.93 nmol/L |
| DHEA-S (ref. 1.65–9.15 µmol/L) | 0.468 µmol/L | 0.494 µmol/L |
| Androstenedione (ref. 3.5 ng/mL) | 1.1 ng/mL | 2.4 ng/mL |